Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

46.7K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.7K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

15
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
15
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

863
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
863

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic performance of Asian Working Group for Sarcopenia 2019 and 2025 sarcopenia definitions in cirrhosis.

Hepatology international·2026
Same author

Nationwide Detection and Molecular Characterization of Hepatitis E Virus RNA in Retail Pork Meat in Japan.

Viruses·2026
Same author

Cell-type-specific actions of carnosic acid against <i>Porphyromonas gingivalis</i>-induced proliferation in liver cancer cells.

Journal of oral microbiology·2026
Same author

Evidence-Based Clinical Practice Guidelines for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 2026.

Hepatology research : the official journal of the Japan Society of Hepatology·2026
Same author

Evidence-based clinical practice guidelines for metabolic dysfunction-associated steatotic liver disease (MASLD) 2026.

Journal of gastroenterology·2026
Same author

Genetic dissection reveals distinct contributions of the eS31 N-terminal domain to translational accuracy in Saccharomyces cerevisiae.

The FEBS journal·2026

Related Experiment Video

Updated: Sep 8, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K

Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with

Kei Endo1, Takuro Sato1, Yuichi Yoshida1

  • 1Division of Hepatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan.

Nutrition (Burbank, Los Angeles County, Calif.)
|June 14, 2022
PubMed
Summary

Direct-acting antiviral therapy for hepatitis C virus (HCV) does not alter serum myostatin levels. This finding suggests viral eradication does not impact myostatin, a protein linked to sarcopenia in chronic liver disease patients.

Keywords:
Hepatitis C virusLiver fibrosis markerSerum myostatinSkeletal muscle indexSustained virologic response

More Related Videos

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.5K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K

Related Experiment Videos

Last Updated: Sep 8, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.9K
Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus
06:28

Immunofluorescence to Monitor the Cellular Uptake of Human Lactoferrin and its Associated Antiviral Activity Against the Hepatitis C Virus

Published on: October 1, 2015

13.5K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.8K

Area of Science:

  • Hepatology
  • Virology
  • Muscle Biology

Background:

  • Myostatin is implicated in sarcopenia development in chronic liver disease.
  • The impact of hepatitis C virus (HCV) elimination on myostatin remains unclear.

Purpose of the Study:

  • To evaluate the effect of sustained virologic response (SVR24) after direct-acting antiviral (DAA) therapy on serum myostatin levels in HCV patients.

Main Methods:

  • Retrospective analysis of 91 HCV patients treated with DAA between 2014-2017.
  • Comparison of serum myostatin levels before and after DAA treatment (SVR24).
  • Correlation analysis between myostatin and laboratory data.

Main Results:

  • No significant difference in myostatin levels before and after DAA therapy (P=0.79).
  • Myostatin levels were higher in men and patients with cirrhosis compared to women and chronic hepatitis patients.
  • Positive correlation observed between myostatin levels and skeletal muscle index and liver fibrosis markers.

Conclusions:

  • HCV viral eradication via DAA therapy does not reduce serum myostatin levels.
  • Myostatin levels are associated with sex and liver disease severity in HCV patients.